标题
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma
作者
关键词
-
出版物
Experimental Hematology & Oncology
Volume 10, Issue 1, Pages -
出版商
Springer Science and Business Media LLC
发表日期
2021-03-05
DOI
10.1186/s40164-021-00213-6
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of dual inhibition of histone deacetylase and phosphatidylinositol-3 kinase in Philadelphia chromosome-positive leukemia cells
- (2020) Seiichi Okabe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia
- (2020) Xinyu Li et al. HAEMATOLOGICA
- Mitochondrial membrane potential
- (2018) Ljubava D. Zorova et al. ANALYTICAL BIOCHEMISTRY
- PI3K/AKT/mTOR pathway in multiple myeloma: from basic biology to clinical promise
- (2018) Vijay Ramakrishnan et al. LEUKEMIA & LYMPHOMA
- Copanlisib, a novel phosphoinositide 3-kinase inhibitor, combined with carfilzomib inhibits multiple myeloma cell proliferation
- (2018) Seiichi Okabe et al. ANNALS OF HEMATOLOGY
- Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
- (2018) Hartmut Goldschmidt et al. ANNALS OF HEMATOLOGY
- Towards personalized treatment in multiple myeloma based on molecular characteristics
- (2018) Charlotte Pawlyn et al. BLOOD
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Histone Deacetylase Inhibitors as Anticancer Drugs
- (2017) Tomas Eckschlager et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial
- (2017) Yasuhiro Oki et al. HAEMATOLOGICA
- Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: an open-label, dose-escalation, phase 1 trial
- (2016) Anas Younes et al. LANCET ONCOLOGY
- Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase
- (2016) Chung-Pu Wu et al. MOLECULAR PHARMACEUTICS
- Frontline therapy of multiple myeloma
- (2015) P. Moreau et al. BLOOD
- New and emerging HDAC inhibitors for cancer treatment
- (2014) Alison C. West et al. JOURNAL OF CLINICAL INVESTIGATION
- Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
- (2014) Jesús F San-Miguel et al. LANCET ONCOLOGY
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
- (2014) Ajay K. Gopal et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Multiple myeloma
- (2013) D. Smith et al. BMJ-British Medical Journal
- Cancer Network Disruption by a Single Molecule Inhibitor Targeting Both Histone Deacetylase Activity and Phosphatidylinositol 3-Kinase Signaling
- (2012) C. Qian et al. CLINICAL CANCER RESEARCH
- NF-κB and the link between inflammation and cancer
- (2012) Joseph A. DiDonato et al. IMMUNOLOGICAL REVIEWS
- Molecular pathogenesis of multiple myeloma and its premalignant precursor
- (2012) W. Michael Kuehl et al. JOURNAL OF CLINICAL INVESTIGATION
- Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
- (2010) T.-C. Chou CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started